QIAGEN N.V. (QGEN) recently announced that Bode Technology will be the exclusive global commercial partner for its GEDmatch PRO genealogy database. QIAGEN's subsidiary Verogen inked the deal with Bode. The company has been providing GEDmatch PRO to customers since the acquisition of its subsidiary, Verogen, in early 2023. The latest partnership is aimed at accelerating the use of QIAGEN's next-generation sequencing (NGS) products in human identification (HID) and forensic investigations. QGEN's Likely Stock ...

Venlo, the Netherlands, and Germantown, Maryland, Sept. 23, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Bode Technology, the largest private U.S. forensics laboratory company with a growing presence in other regions, would become the exclusive global commercial partner for the GEDmatch PRO genealogy database, which is used to assist police and forensic teams with investigative comparisons of genetic data. The multi-year agreement between QIAGEN's sub ...

QIAGEN N.V. (QGEN) recently announced the launch of 100 new assays for its digital polymerase chain reaction (dPCR) platform — QIAcuity. The assays will be used to study cancer, inherited genetic disorders, infectious disease surveillance, and food and environmental monitoring. These are available through QIAGEN's comprehensive GeneGlobe platform. The latest launch will be an addition to the company's PCR product portfolio. QGEN's Likely Stock Trend Following the News Shares of QGEN were up 0.04% in pre-mar ...

Core Insights - QIAGEN has launched 100 new assays for its QIAcuity digital PCR platform, targeting applications in cancer research, genetic disorders, infectious disease surveillance, and environmental monitoring [1][2][3] - The company has exceeded its 2024 goal by launching over 130 new assays this year, contributing to a total of more than 2,300 validated assays [2] Product Development - The new assays include dPCR LNA Mutation and dPCR CNV Probe Assays, focusing on cancer-related mutations and copy number variations in genes associated with various cancers [3][4] - dPCR Microbial DNA Detection Assays are designed to identify pathogens linked to infectious diseases and antibiotic resistance, as well as animal and plant diseases [4] Market Adoption - QIAcuity digital PCR has seen strong adoption, with over 2,000 placements by the end of 2023 and citations in over 450 publications, serving key customers in pharmaceuticals, academia, and diagnostics [5] Technological Advancements - The QIAcuity platform utilizes nanoplates for sample partitioning, allowing simultaneous reading of reactions, which reduces processing time from six hours to two [6] - The platform is available in one-, four-, and eight-plate versions, catering to various laboratory sizes and throughput needs [6] Future Plans - An in-vitro diagnostic version of QIAcuity is set to launch in fall 2024, aimed at clinical applications such as diagnosing infectious diseases and monitoring cancer [7] - QIAGEN is collaborating with pharmaceutical companies to develop companion diagnostics using the QIAcuity platform [7]

QIAGEN's (QGEN) business is expected to get a boost from its growing molecular diagnostic market, expanded test menu and growth-driving strategic collaborations. Yet, a challenging macro environment and an intensely competitive market may dent its results of operations. The stock carries a Zacks Rank #3 (Hold) currently. Factors Driving Growth for QGEN Stock QIAGEN offers one of the broadest portfolios of molecular technologies for healthcare. Its range of assays for diseases and biomarkers speeds up and si ...

QIAGEN N.V. (QGEN) announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, a leading vaccines and diagnostics supplier to the Brazilian Ministry of Health. Initiated in 2009, the expanded collaboration allows Bio-Manguinhos to launch an advanced PCR (Polymerase Chain Reaction)-based molecular screening platform to detect malaria alongside HIV, hepatitis B and C virus, a capability previously unavailable in Brazil's blood donation program. The recent development will also support ep ...

Venlo, the Netherlands, Rio de Janeiro, Brazil, Sept. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its strategic partnership with BioManguinhos/Fiocruz, the leading provider of vaccines and diagnostics to the Brazilian Ministry of Health. The partnership, initiated in 2009, supported Bio-Manguinhos/Fiocruz with reagents and instruments for testing samples for HIV and hepatitis C virus. With the expansion of this collaboration, Bio-Manguinho ...

Venlo, the Netherlands, Sept. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a collaboration with Eli Lilly and Company to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes which can play a role in the diagnosis of Alzheimer's disease. This collaboration represents a significant milestone as the QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping. The panel will be int ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the final terms of the new senior ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN") announces certain terms of the new senior, unsecured net sha ...